Загрузка...
Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study
OBJECTIVES: To examine the safety of an agonist-type treatment, lisdexamfetamine (LDX), at 250 mg/day among adults with methamphetamine (MA) dependence. DESIGN: A dose-escalating, phase-2, open-label, single-group study of oral LDX at two Australian drug treatment services. SETTING: The study was co...
Сохранить в:
| Опубликовано в: : | BMJ Open |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Publishing Group
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8137170/ https://ncbi.nlm.nih.gov/pubmed/34006547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-044696 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|